From the medical front, Vancouver-based Sirona Biochem Corp. (TSX-Venture:SBM) has made breakthroughs, reporting Wednesday of dazzling results of a clinical trial performed in the Peoples Republic of China (China) using Sirona's novel skin lightening agent TFC-1067.
Sirona's TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.
Sirona Biochem Chief Scientific Officer Géraldine Deliencourt-Godefroy said "These are excellent clinical results. Based on the outcome from our first clinical trial, we are pleased to see such results for the short four-week duration of the testing.
This positive testing result on Asian skin with the observed lightening effect supports the clinical effect of TFC-1067 over different skin types. A longer trial is required to assess dyschromia which was assessed in Sirona's U.S. based clinical trial. Sirona will await feedback on the further testing currently ongoing in China with our new formulation."
A World Health Organization survey reported that nearly 40% of women polled in China said they regularly used whitening products many of which are toxic.
Shares in SBM rocketed 3.5 cents, or 9.7%, to 39.5 cents, on more than five million shares.